Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space.

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer ...

PFE is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of PFE shares has increased $0.03 since the market last closed. This is a 0.11% ...

Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1). A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue. Pfizer's stock appears to be in bargain ...

Deep-pocketed investors have adopted a bearish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...